

+ A natural choice for  
gentle and selective  
debridement



**Smith+Nephew**

**IRUXOL<sup>◇</sup> MONO**  
Collagenase Ointment 1.2U

 G1633 (Act 101/1965)

Helping you get **CLOSER TO ZERO<sup>◇</sup>**  
human and economic consequence of wounds  
[smith-nephew.com](http://smith-nephew.com)

# + Enzymatic debridement is a selective debridement method.

## Features and benefits

IRUXOL® MONO Ointment is indicated for the enzymatic debridement of necrotising wounds. Its active component, collagenase, helps break down native collagen in the wound. Iruxol MONO has been shown to provide removal of necrotic tissue from the wound bed<sup>1</sup>. IRUXOL MONO Ointment is an enzyme based product that acts selectively on collagen, freeing the wound of necrotic material so that healing can proceed. IRUXOL MONO is selective and effective.<sup>1-3</sup>

### Selective

IRUXOL MONO Ointment is an enzyme based product that acts selectively on Collagen.<sup>2</sup>

### Effective

IRUXOL MONO Ointment is supported by more than 20 years of successful use on a variety of chronic wound types.<sup>1</sup>

## Application

1. Clean wound with saline.
2. Apply a layer of IRUXOL MONO Ointment to an approximate depth of 2mm.
3. Cover with an appropriate secondary dressing.
4. Repeat the dressing change every 24 hours until all necrotic tissue has been removed. Occasionally, a twice daily change may be necessary.
5. To remove, rinse with saline.

IRUXOL MONO Ointment should be used until debridement of tissue is complete and granulation tissue is well established.

## Local prescribing information

## Indications

IRUXOL MONO ointment contains clostridiopeptidase (a collagenase enzyme) and protease enzymes.

These enzymes can be used to remove dead tissue (debride) from wounds such as leg ulcers, diabetic ulcers and pressure sores. By removing the dead tissue, IRUXOL MONO ointment cleanses the wound and speeds up wound healing.

## Contraindications

Do not use IRUXOL MONO ointment if you are allergic to protease enzymes or any of the other ingredients of this medicine (listed in IFU).

### Take special care with IRUXOL MONO ointment if:

you are diabetic and have been told that the wound contains dry gangrenous material.

**If you are using other medicines please see following section.**

### Using other medicines

IRUXOL MONO ointment should not be used if you are applying other products to the wound that may interfere with the medicine such as: antiseptics, antibiotics (tyrothricin, gramicidin and tetracyclines), heavy metals, detergents and soaps. Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.

### Pregnancy and breast-feeding

Do not use IRUXOL MONO ointment if you know, or think you may be, less than three months pregnant, unless the doctor has told you to. The ointment is safe to use if you are more than three months pregnant and while breast-feeding. Ask your doctor or pharmacist for advice before taking or using any medicines.

Advanced Wound Management  
Smith & Nephew Medical Ltd  
Building 5, Hatters Lane - Watford  
Hertfordshire WD18 8YE - UK  
T +44 (0) 1923 477100  
F +44 (0) 1923 477101

[www.smith-nephew.com](http://www.smith-nephew.com)

♦Trademark of Smith+Nephew  
All Trademarks acknowledged  
© May 2021 Smith+Nephew  
AWM-AWC-28711

For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product's applicable Instructions for Use (IFU) prior to use. For full prescribing information please refer to the package insert approved by the Medicine's Regulatory Authority.